clinical trial · NCT07219173
A Study to Evaluate Brenipatide Compared With Placebo in Adult Participants With Uncontrolled Moderate to Severe Asthma
Eli Lilly and Company·phase2·recruiting·n = 531
AsthmaBrenipatideBrenipatidePlacebo
brief summary
The purpose of this study is to assess the safety and efficacy of brenipatide at different dose levels compared with placebo in participants with moderate-to-severe asthma. Study participation will last approximately 65 weeks, including screening, treatment, and follow-up periods.
started
Oct 22, 2025
primary completion
Apr 1, 2028
completion
Jun 1, 2028
last updated
Apr 17, 2026
official title
A Phase 2, Multicenter, Randomized, Double-blind, 52-week Study, to Investigate the Efficacy and Safety of Brenipatide Compared With Placebo for the Treatment of Adult Participants With Uncontrolled Moderate to Severe Asthma
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol